Introduction
============

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer, and distant organ metastasis is the leading cause of death in these patients, with a 5-year survival rate of less than 15% ([@ref-21]; [@ref-25]). In advanced-stage lung cancer, metastasis sites of distant organs, including brain, bone and liver, are common ([@ref-19]). Among the distant metastases, liver metastasis in NSCLC patients confers the worst prognosis, even worse than brain metastases, with a median overall survival of 3 months ([@ref-19]; [@ref-22]). Despite recent advances in various treatment strategies, no local consolidation therapies of liver metastases have been established in clinical practices ([@ref-10]; [@ref-11]). Therefore, increased knowledge of the risk factors for liver metastasis may be an effective strategy for lowering the incidence of this lethal disease.

Non-alcoholic fatty liver disease (NAFLD) is one of the most common hepatic disorders worldwide, and is significantly associated with obesity and age ([@ref-1]). Currently, the population prevalence of NAFLD in Asia is approximately 25%, comparable to Western countries ([@ref-6]). Therefore, NAFLD is commonly encountered in many cancer patients, such as NSCLC patients, in clinical oncology practices. The histological hallmark of NAFLD is hepatic steatosis (HS), which can lead to a liver lesion that is characterized by hepatocyte injury and inflammation changes with or without fibrosis ([@ref-9]). Given that the poor prognosis of NSCLC patients with liver metastasis and NAFLD are endemic worldwide, it is important to clarify the association between HS and liver metastasis in NSCLC patients.

Recently, opinions abound on whether liver metastasis could be affected by HS have no consistent conclusion. In patients with colorectal cancer, two observational studies just reported conflicting results. [@ref-7] suggested that HS was an independent risk factor for liver metastasis in patients with colorectal cancer. On other hand, [@ref-16] reported that liver metastases derived from colorectal cancer occur less frequently in patients with HS. In breast cancer, it has been reported that liver metastases rarely occur in patients with HS ([@ref-26]).

However, to the best of our knowledge, no study to date has investigated the relationship between HS and liver metastasis in patients with NSCLC. Therefore, the objective of the current two-center cohort study was to determine whether liver metastasis of NSCLC patients with no distant metastases could be influenced by HS.

Materials and Methods
=====================

Study population
----------------

From January 1, 2005 to December 31, 2015, we conducted this two-center cohort study of patients with NSCLC, at two hospitals affiliated with the Southern Medical University (Guangzhou, China), Nanfang Hospital and Zhujiang Hospital. In total, 1,873 patients with new pathologically diagnosed NSCLC were enrolled in this two-center retrospective study. The clinicopathological information, including sex, age, date of NSCLC diagnosis, date of liver metastasis, tumor histology, treatment and laboratory data, was reviewed from hospital medical records. The clinical staging was determined based on the tumor, node, metastasis classification of the AJCC system (7th edition, 2010).

The inclusion criteria were as follows: (1) patients with histopathologically confirmed NSCLC, (2) patients who had undergone an abdominal ultrasound (US) within a month of the NSCLC diagnosis, and (3) patients who did not consume excessive amounts of alcohol.

The exclusion criteria were as follows: (1) patients with distant metastases at that time of the NSCLC diagnosis, (2) patients with other malignant tumors, and (3) patients with follow-up times of fewer than 30 days.

The study protocol protected the patients' private information according to the precepts of the Helsinki Declaration. Additionally, approvals were acquired from the Institutional Review Boards of the Nanfang Hospital and Zhujiang Hospital of Southern Medical University (2017-zlk-009).

Laboratory tests
----------------

As hepatitis B virus is prevalent in China, the sera of all patients were screened for hepatitis B surface antibody and hepatitis C virus antibody using ELISA (enzyme-linked immunosorbent assay). In addition, patients who underwent radiotherapy or chemotherapy routinely received liver function tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin levels every 2 weeks during treatment or at each follow-up visit.

Imaging evaluation of the liver, metastasis assessment, follow-up and treatment
-------------------------------------------------------------------------------

Compared with pathological biopsy as a standard method, US was found to have high specificity and sensitivity for the detection of fatty liver ([@ref-4]; [@ref-8]); all patients treated in the two study hospitals routinely had an US to check for liver diseases at that time of diagnosis or during follow-ups.

In accordance with the guidelines for the assessment and management of NAFLD in the Asia-Pacific region ([@ref-18]), the diagnosis of NAFLD can be based on the following factors: (1) the imaging results are consistent with the diagnostic criteria of fatty liver disease, in which is a liver fat content of \>5% is considered diagnostic of NAFLD, (2) no history of alcohol intake more than 30 g for males or 20 g for females per day, and (3) exclusion of other diseases that can lead to steatosis.

Based on the abdominal US results, patients were divided into the study group and control group. Therefore, the patients with HS were included in the study (HS) group, and others without HS were regarded as in the control (non-HS) group.

All patients underwent routine imaging assessments, including abdominal US or computed tomography (CT), thoracic radiography, CT, or magnetic resonance imaging (MRI), brain CT and whole-body bone scans at the time of diagnosis or during follow-ups, and their metastatic status was evaluated by imaging specialists. Routine abdominal US were performed during follow-up, and if the results showed a potential liver metastasis, further validation was performed via CT or MRI. Alternatively, the liver metastasis was diagnosed directly by CT or MRI in the absence of US. All imaging records were evaluated separately by two specialized radiologists to increase the accuracy of metastatic status diagnosis; disagreements were resolved by consensus.

The duration of follow-ups was calculated from the day of the histopathological biopsy to the date of diagnosis of liver metastasis, or to the last imaging examination. The formulation of the follow-up protocols and treatments were implied referring to the NCCN Clinical Practice Guidelines of NSCLC. The last follow-up date was December 31, 2017.

Statistical analysis
--------------------

We compared the clinicopathological factors in two groups using χ^2^ tests or Fisher's exact tests, as indicated. The Kaplan--Meier method was used to calculate liver and overall metastasis-free survival (MFS) rates, and the differences in survival for univariate comparisons were calculated by using the log-rank test. To determine the potential effect modification by age, gender, ALT or AST level, hepatitis virus, diabetes mellitus, and BMI, an interaction analysis was calculated by adding the respective categorical variable product terms individually to the model. A Cox regression analysis was used to analyze univariate and multivariate analyses for liver and overall metastasis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to show the results.

SPSS statistical software (version 20; IBM Corporation, Chicago, IL, USA) was used for all analyses. The criterion for statistical significance was determined by two-tailed *P*-values less than 0.05.

Results
=======

Baseline parameters of NSCLC patients
-------------------------------------

A total of 1,873 patients (878 from Nanfang Hospital and 995 from Zhujiang Hospital) were conformed for the analysis during the study period. A total of 408 (21.8%) patients were diagnosed with HS. Thus, 408 (21.8%) patients with HS were included in the study group, and 1,465 (78.2%) patients were regarded as the control group.

The median follow-up time was 14.5 ± 16.2 months (range, 1--131 months) in the study population. The mean age of all patients was 58.9 ± 11.1 years. The monitored endpoints were the liver and overall MFS rates. There were 762 patients with distant organ metastases. Liver metastases were observed in 58 (14.2%) of 408 patients in the study group and 108 (7.4%) of 1,465 patients in the control group, suggesting that the liver metastasis rate in the study group was significantly higher compared with the control group (*P* \< 0.001; χ^2^ test).

Baseline parameters of the study and control groups and differences in the distribution of covariables are listed in [Table 1](#table-1){ref-type="table"}. There were no significant differences in the T classification, N classification, histology, surgery, chemotherapy or radiotherapy between the two groups. However, higher proportions of HS were observed in younger patients (aged \<60 years; *P* \< 0.001), in male patients (*P* = 0.002), and in patients without the hepatitis virus infection (9.1% vs. 12.8%; *P* = 0.039). Furthermore, HS was found at a higher incidence in obese (BMI ≥ 25 kg/m^2^) patients and patients with diabetes mellitus (*P* \< 0.001 and *P* = 0.015, respectively). Moreover, a high level of the ALT or AST was significantly more common in the study group compared with the control group (14.0 vs. 7.8%, *P* \< 0.001).
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###### Baseline characteristics of the NSCLC patients.
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  Characteristic      Study group (408)   Control group (1,465)   *P*-value
  ------------------- ------------------- ----------------------- -----------
  Age                                                             \<0.001
   \<60 years         275 (67.4)          724 (49.4)              
   ≥60 years          133 (32.6)          741 (50.6)              
  Gender                                                          0.002
   Male               315 (77.2)          1,015 (69.3)            
   Female             93 (22.8)           450 (30.7)              
  T category                                                      0.705
   T1                 52 (12.7)           173 (11.8)              
   T2                 155 (38.0)          533 (36.4)              
   T3                 76 (18.6)           309 (21.1)              
   T4                 125 (30.6)          450 (30.7)              
  N category                                                      0.370
   N0                 105 (25.7)          377 (25.7)              
   N1                 45 (11.0)           145 (9.9)               
   N2                 150 (36.8)          601 (41.0)              
   N3                 108 (26.5)          342 (23.3)              
  Pathological type                       0.298                   
   Squamous           133 (32.6)          519 (35.4)              
   Non-squamous       275 (67.4)          946 (64.6)              
  ALT or AST level                                                \<0.001
   \<40 U/L           351 (86.0)          1,350 (92.2)            
   ≥40 U/L            57 (14.0)           115 (7.8)               
  Hepatitis virus                                                 0.039
   Present            37 (9.1)            188 (12.8)              
   Absent             371 (90.9)          1,277 (87.2)            
  Diabetes mellitus                                               0.015
   Yes                45 (11.0)           107 (7.3)               
   No                 363 (89.0)          1,358 (92.7)            
  BMI                                                             \<0.001
   \<25 kg/m^2^       240 (58.8)          1,183 (80.8)            
   ≥25 kg/m^2^        168 (41.2)          282 (19.2)              
  Surgery                                                         0.235
   Yes                157 (38.5)          517 (35.3)              
   No                 251 (61.5)          948 (64.7)              
  Chemotherapy                                                    0.654
   Yes                372 (91.2)          1,325 (90.4)            
   No                 36 (8.8)            140 (9.6)               
  Radiotherapy                                                    0.360
   Yes                96 (23.5)           328 (22.4)              
   No                 312 (76.5)          1,137 (77.6)            

**Note:**

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index.

Prognostic factors for liver metastasis-free survival
-----------------------------------------------------

The liver MFS rates are shown in [Fig. 1](#fig-1){ref-type="fig"}. The 5-year liver MFS rates were 54.1% and 78.7% in the study group and control group, respectively, indicating that patients in the study group had a significantly worse liver MFS (*P* = 0.031). Furthermore, in the univariate Cox regression analysis, HS was associated with poorer liver MFS.

![Kaplan--Meier curves of liver metastasis-free survival for NSCLC patients, stratified by HS.](peerj-07-6612-g001){#fig-1}

In the multivariate Cox regression analysis adjusted for all confounders, HS was considered an independent adverse factor for liver metastasis (HR 1.43; 95% CI \[1.02--2.01\]; *P* = 0.039) ([Table 2](#table-2){ref-type="table"}). Moreover, advanced N classification (N1, N2, and N3) was associated with an increased risk of liver metastasis in the NSCLC patients. In contrast, surgery (HR 0.57; 95% CI \[0.38--0.84\]; *P* = 0.005) and radiotherapy (HR 0.57; 95% CI \[0.39--0.83\]; *P* = 0.003) were found to be independent protective factors for liver metastasis ([Table 2](#table-2){ref-type="table"}), which is consistent with previous studies. In the subgroup analysis ([Fig. 2](#fig-2){ref-type="fig"}), there were no significant interactions in age, gender, diabetes mellitus, or BMI, with overall *P*-values of 0.501, 0.073, 0.141, and 0.832, respectively; except for AST or ALT level and hepatitis virus (*P*~interaction~ = 0.028 and *P*~interaction~ \< 0.001, respectively).
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###### Univariate and multivariate analyses for liver metastasis.
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  Parameter            Univariate analysis   Multivariate analysis                       
  -------------------- --------------------- ----------------------- ------------------- ---------
  Age ≥60 years        1.03 (0.76--1.40)     0.839                   0.96 (0.70--1.31)   0.788
  Gender: Male         1.18 (0.84--1.66)     0.335                   1.22 (0.86--1.74)   0.268
  T category                                                                             
   T1                  1                                             1                   
   T2                  2.23 (1.20--4.15)     0.011                   1.93 (1.03--3.61)   0.042
   T3                  2.20 (1.12--4.33)     0.022                   1.41 (0.70--2.82)   0.335
   T4                  3.02 (1.62--5.63)     \<0.001                 1.77 (0.93--3.39)   0.082
  N category                                                                             
   N0                  1                                             1                   
   N1                  1.10 (0.51--2.39)     0.817                   1.01 (0.46--2.21)   0.990
   N2                  3.10 (1.92--4.99)     \<0.001                 2.71 (1.65--4.47)   \<0.001
   N3                  4.52 (2.75--7.42)     \<0.001                 3.59 (2.10--6.13)   \<0.001
  Histology squamous   1.27 (0.93--1.74)     0.140                   1.28 (0.93--1.77)   0.140
  ALT or AST ≥40 U/L   0.97 (0.57--1.66)     0.923                   0.81 (0.47--1.42)   0.467
  Hepatitis virus      1.25 (0.81--1.93)     0.306                   1.30 (0.83--2.04)   0.246
  Diabetes mellitus    1.10 (0.66--1.85)     0.707                   1.12 (0.67--1.90)   0.662
  BMI ≥25 kg/m^2^      1.27 (0.90--1.78)     0.177                   1.07 (0.75--1.53)   0.709
  Hepatic Steatosis    1.42 (1.03--1.96)     0.032                   1.43 (1.02--2.01)   0.039
  Surgery              0.45 (0.31--0.63)     \<0.001                 0.57 (0.38--0.84)   0.005
  Chemotherapy         1.21 (0.20--2.09)     0.504                   0.76 (0.43--1.34)   0.346
  Radiotherapy         0.72 (0.50--1.05)     0.087                   0.57 (0.39--0.83)   0.003

**Note:**

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HR, hazard ratio; CI, confidence interval.

![Subgroup analyses of liver metastasis-free survival comparing the study and control populations.](peerj-07-6612-g002){#fig-2}

As obesity is reported to be a risk factor for HS and is significantly associated with BMI, the overweight and non-overweight groups were analyzed. As shown in [Fig. 3A](#fig-3){ref-type="fig"}, for the outcome of overweight (BMI ≥25 kg/m^2^) patients, HS was not associated with liver MFS (*P* = 0.280). However, in the non-overweight group (BMI \<25 kg/m^2^), HS was associated with a significantly worse prognosis in the liver MFS (*P* = 0.003) ([Fig. 3B](#fig-3){ref-type="fig"}). Similarly, we analyzed the impact of age among the patients with HS. As shown in [Fig. 4A](#fig-4){ref-type="fig"}, in the older age (age ≥60 years) group, the association of liver MFS was not observed in patients with or without HS. On the other hand, in patients with HS, younger age (age \<60 years) was associated with a worse liver MFS (*P* = 0.028) ([Fig. 4B](#fig-4){ref-type="fig"}).

![Impact of BMI on the association between HS and liver metastasis.\
(A) No significant differences of liver MFS were observed between the patients with and without HS among the overweight patients. (B) Non-overweight (BMI \<25 kg/m^2^) patients with HS had significantly worse liver MFS (*P* = 0.003) compared to those without HS.](peerj-07-6612-g003){#fig-3}

![Impact of age on the association between HS and liver metastasis.\
(A) No significant differences of liver MFS were observed between patients with and without HS among the older patients. (B) Younger (age \<60 years) patients with HS had significantly worse liver MFS (*P* = 0.028) compared to those without HS.](peerj-07-6612-g004){#fig-4}

Prognostic factors for overall metastasis-free survival
-------------------------------------------------------

The overall MFS was calculated from the date of the histological biopsy to the date of diagnosis of the first metastatic site, or to the last examination. As the overall MFS rates are shown in [Fig. 5](#fig-5){ref-type="fig"}, we found there was no significant differences in overall MFS rates between the two groups (*P* = 0.693).

![Kaplan--Meier curves of overall metastasis-free survival for NSCLC patients, stratified by HS.](peerj-07-6612-g005){#fig-5}

In the multivariate Cox regression analysis adjusted for all confounders, surgery (HR 0.53; 95% CI \[0.44--0.64\]; *P* \< 0.001) and squamous histology (HR 0. 75; 95% CI \[0.64--0.88\]; *P* = 0.001) were found to be independent favorable factors for the overall MFS ([Table 3](#table-3){ref-type="table"}). However, advanced T classification (T2, T3, and T4) and advanced N classification (N2 and N3) were associated with increased risks of overall metastasis in NSCLC patients.
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###### Univariate and multivariate analyses for overall metastasis.
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  Parameter            Univariate analysis    Multivariate analysis                         
  -------------------- ---------------------- ----------------------- --------------------- ---------
  Age ≥60 years        1.00 \[0.87--1.16\]    0.959                   0.95 \[0.82--1.10\]   0.490
  Gender. male         1.00 \[0.86--1.17\]    0.97                    1.10 \[0.94--1.29\]   0.248
  T category                                                                                
   T1                  1                                              1                     
   T2                  2.23 \[1.71--3.10\]    \<0.001                 1.90 \[1.40--2.57\]   \<0.001
   T3                  2.29 \[2.12--3.99\]    \<0.001                 1.92 \[1.39--2.65\]   \<0.001
   T4                  3.29 \[2.44--4.42\]    \<0.001                 1.97 \[1.45--2.67\]   \<0.001
  N category                                                                                
   N0                  1                                              1                     
   N1                  1.52 \[1.11--2.11\]    0.010                   1.28 \[0.92--1.77\]   0.141
   N2                  3.19 \[2.56--3.97\]    \<0.001                 2.41 \[1.92--3.02\]   \<0.001
   N3                  3.87 \[3.07--4.88\]    \<0.001                 2.52 \[1.97--3.22\]   \<0.001
  Histology squamous   0.78 \[0.67--0.92\]    0.002                   0.75 \[0.64--0.88\]   0.001
  ALT or AST ≥40 U/L   1.30 \[1.04--1.62\]    0.023                   1.14 \[0.90--1.44\]   0.285
  Hepatitis virus      1.26 \[1.03--1.54\]    0.026                   1.21 \[0.98--1.50\]   0.071
  Diabetes mellitus    1.0 2 \[0.79--1.31\]   0.898                   1.09 \[0.84--1.41\]   0.520
  BMI ≥25 kg/m^2^      1.13 \[0.96--1.33\]    0.152                   1.05 \[0.89--1.24\]   0.584
  Hepatic steatosis    1.03 \[0.88--1.21\]    0.693                   0.99 \[0.84--1.17\]   0.895
  Surgery              0.38 \[0.32--0.49\]    \<0.001                 0.53 \[0.44--0.64\]   \<0.001
  Chemotherapy         2.07 \[1.52--2.82\]    \<0.001                 1.22 \[0.89--1.67\]   0.224
  Radiotherapy         1.43 \[1.23--1.67\]    \<0.001                 1.13 \[0.97--1.33\]   0.119

**Note:**

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HR, hazard ratio; CI, confidence interval.

Discussion
==========

Until now, the adverse factors for liver metastasis in patients with NSCLC have been far from well defined. To the best of our knowledge, the present study is the first-scale cohort study to analyze the effect of HS in NSCLC patients with no distant metastases. Among the patients in our study, the prevalence of the NAFLD was 21.8%, which is consistent with that of the NSCLC patients in China ([@ref-6]; [@ref-29]) Moreover, the current study also found that HS was more common in younger (age \<60 years) and male patients with NSCLC. Based on previous studies, NAFLD is common in middle-age male patients, and then declines after 50--60 years of age ([@ref-17]; [@ref-27]). Consequently, this observed trend in our study is reasonable.

In this study, patients in the HS group had a significantly higher rate of liver metastasis compared with the control group. Further multivariate analyses suggested that HS was an independent risk factor for liver metastasis in patients with NSCLC, while HS had no significant effects on the development of overall metastasis. It is well-known that liver metastasis is a serious adverse prognostic factor for the overall survival of patients with NSCLC, but clinicopathological risk factors for the liver metastasis of NSCLC have not yet been well identified. Our findings provide evidence that HS is a significant risk factor in the development of liver metastasis, and may provide valuable ideas for future research.

Inflammation plays a key role in tumor progression, and it has been reported that changes in the microenvironment caused by inflammation contribute to metastasis ([@ref-3]). Thus, we hypothesized that HS might be a risk factor for liver metastasis in patients with NSCLC, possibly by providing a favorable microenvironment for metastasis of tumor cells. In fact, several studies have reported that hepatic stellate cells can be activated by steatosis ([@ref-12]; [@ref-15]), which could play a key role in the progression of organizing and promoting metastasis, and organizing angiogenesis during the development of liver metastasis ([@ref-5]; [@ref-14]). Furthermore, in a murine model, dietary fat increased metastatic tumor growth in the NAFLD microenvironment after the intrasplenic injection of colon cancer cells ([@ref-24]).

Additionally, copper has been found to contribute to the metastatic progression of cancers, which is a key component of several enzymes critical to remodeling the tumor microenvironment ([@ref-2]). Interestingly, serum copper levels were higher in lung cancer patients than in the healthy people ([@ref-28]). Although low copper levels may contribute to the pathogenesis of NAFLD ([@ref-23]), until now, there is no literature to report the effect of HS on copper metabolism. Moving forward, we hypothesize that HS inhibits the conversion of copper into compounds in liver tissue, as copper compounds were found to have promising anticancer properties ([@ref-20]). Consequently, further mechanistic studies are needed to study the HS microenvironment in NSCLC patients with HS.

The results of this study provide evidence of the effect of HS on the development of liver metastasis in patients with no distant metastatic NSCLC. Consequently, researchers in clinical trials of patients with NSCLC should pay attention to the prevalence rate of HS in different treatment groups, especially in China where the incidence of NAFLD is increasing rapidly ([@ref-13]). Thus, the management guidelines of NSCLC should consider patients with HS.

The current study has several limitations. First, as this was a retrospective study, there may be present some selection biases, and the incidence of liver metastasis was low. In addition, the loss to follow-up bias might have affected the outcomes due to the high mortality of NSCLC, and the sample size for this study was limited (408 patients in the study group). Therefore, these results need to be validated by a prospective study of a larger cohort. Second, NAFLD and liver metastasis were mainly evaluated via imaging examination and not validated by biopsy, which may lead to false positive diagnoses, although the results were evaluated separately by two radiologists. Pathological findings can be used to provide evidence in terms of microenvironment changes in the liver. Finally, due to the limitations of imaging results and laboratory data, we could not be able to study the impact of liver metastasis at different levels of HS.

Conclusion
==========

In this study, the data indicate that HS is a risk factor for liver metastasis in patients with no distant metastatic NSCLC. The finding of the current study offers meaningful suggestions regarding the potential crosstalk between metastases of tumor cells and the liver microenvironment, suggesting that more investigations should focus on the impact of HS on the progression of NSCLC. Further studies, including histopathologic investigations of liver tissue to confirm HS, should help clarify any potential relationship between HS and liver metastasis of NSCLC.
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###### Raw data.

followup1 was calculated from the day of the histopathological biopsy to the date of diagnosis of liver metastasis, or to the last imaging examination. followup2 was calculated from the date of the histological biopsy to the date of diagnosis of the first metastatic site, or to the last examination.

###### 

Click here for additional data file.
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